The EC Opens Antitrust Investigation Against Vifor Pharma’s Anti-Competitive Disparagement for Iron Deficiency Treatment
Shots:
- The EC had opened formal proceedings to determine whether Vifor Pharma had disparagement of its closest rival Pharmacosmos to hinder competition against blockbuster iron deficiency therapy, Ferinject
- Vifor Pharma may be defaming Monofer by disseminating false information about its safety. If the Commission's concerns are validated, Vifor Pharma's actions may be considered an abuse of dominant position, in violation of Articles 102 of the TFEU and 54 of the EEA Agreement
- Vifor Pharma conducted a deceptive communication campaign, primarily aimed at healthcare professionals, which may have hampered Monofer's acceptance in the EEA
Ref: European | Image: Vifor Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
